- Publikationen

Publikationen

Zurück zu

Literaturverzeichnis:

  • Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, Bockisch A, Phelps ME, Czernin J, Weber WA. Metabolic imaging allows early prediction of response to vandetanib. J Nucl Med. 2011 Feb;52(2):231-40.
  • Stahl AR, Heusner TA, Hartung V, Nagarajah J, Bockisch A, Hahn S, Antoch G, Jentzen W. Time course of tumor SUV in 18F-FDG PET of breast cancer: presentation of a simple model using a single reference point for time corrections of tumor SUVs. J Nucl Med. 2011 Jan;52(1):18-23.
  • Nagarajah J, Sheu-Grabellus SY, Leitzen C, Hartung V, Schmid KW, Bockisch A, Görges R. [Optimization of the fine needle aspiration biopsy (FNAB) of thyroid nodules- automatic aspirator versus manual technique]. Nuklearmedizin. 2011;50(5):189-94. German.
  • Herbrik M, Treffert J, Geiger B, Riegger C, Hartung V, Rosenbaum-Krumme SJ, Forsting M, Antoch G, Heusner TA. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients. J Nucl Med. 2011 Oct;52(10):1520-5.
  • Nagarajah J, Jentzen W, Hartung V, Rosenbaum-Krumme S, Mikat C, Heusner TA, Antoch G, Bockisch A, Stahl A. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1862-8.
  • Hartung-Knemeyer V, Müller S, Nagarajah J, Lahner H, Broecker-Preuss M, Bockisch A, Görges R. Influence of the calcitonin assay on the definition of biochemical cure in patients with medullary thyroid carcinoma. Nuklearmedizin. 2012;51(4):125-32. doi: 10.3413/Nukmed-0454-11-12. German.
  • Nagarajah J, Dannat T, Hartung V, Bockisch A, Rosenbaum-Krumme S. 18F-fluoride PET/CT for bone scanning. Role of attenuation correction. Nuklearmedizin. 2012;51(3):84-7.
  • Hahn S, Hecktor J, Grabellus F, Hartung V, Pöppel T, Kimmig R, Forsting M, Antoch G, Heusner TA. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients. Acta Radiol. 2012 Jun 1;53(5):518-23.
  • Hartung-Knemeyer V, Nagarajah J, Jentzen W, Ruhlmann M, Freudenberg LS, Stahl AR, Bockisch A, Rosenbaum-Krumme SJ. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies. Ann Nucl Med. 2012 Nov;26(9):723-9. doi: 10.1007/s12149-012-0632-1.
  • Riegger C, Köninger A, Forsting M, Hartung V, Otterbach F, Kimmig R, Bockisch A, Antoch G. Comparison of the diagnostic accuracy of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients. Acta Radiol. 2012 Dec 1;53(10):1092-8.
  • Buchbender C, Hartung-Knemeyer V, Beiderwellen K, Heusch P, Kühl H, Lauenstein TC, Forsting M, Antoch G, Heusner TA. Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: Does it benefit lesion detection? Eur J Radiol. 2013 Feb 18.
  • Heusch P, Buchbender C, Beiderwellen K, Nensa F, Hartung-Knemeyer V, Lauenstein TC, Bockisch A, Forsting M, Antoch G, Heusner TA. Standardized uptake values for [(18)F] FDG in normal organ tissues: Comparison of whole-body PET/CT and PET/MRI. Eur J Radiol. 2013 Feb 7.
  • Buchbender C, Hartung-Knemeyer V, Heusch P, Heusner TA, Beiderwellen K, Wittsack HJ, Kühl H, Forsting M, Bockisch A, Antoch G, Lanzman RS. Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system? Eur J Radiol. 2013 Feb;82(2):380-4.
  • Hartung-Knemeyer V, Beiderwellen KJ, Buchbender C, Kuehl H, Lauenstein TC, Bockisch A, Poeppel TD. Optimizing Positron Emission Tomography Image Acquisition Protocols in Integrated Positron Emission Tomography/Magnetic Resonance Imaging. Invest Radiol. 2013 May;48(5):290-4. doi: 10.1097/RLI.0b013e3182823695.
  • Buchbender C, Hartung-Knemeyer V, Forsting M, Antoch G, Heusner TA. Positron emission tomography (PET) attenuation correction artefacts in PET/CT and PET/MRI. Br J Radiol. 2013 May;86(1025):20120570.
  • Beiderwellen KJ, Poeppel TD, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A, Lauenstein TC. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol. 2013 May;48(5):273-9.
  • Heusch P, Köhler J, Wittsack HJ, Heusner TA, Buchbender C, Poeppel TD, Nensa F, Wetter A, Gauler T, Hartung V, Lanzman RS. Hybrid [18F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): Preliminary results in non-small cell lung cancer (NSCLC). Eur J Radiol. 2013 Jul 4.
  • Beiderwellen K, Gomez B, Buchbender C, Hartung V, Poeppel TD, Nensa F, Kuehl H, Bockisch A, Lauenstein TC. Depiction and characterization of liver lesions in whole body [¹?F]-FDG PET/MRI. Eur J Radiol. 2013 Nov;82(11):e669-75.
  • Heusch P, Buchbender C, Köhler J, Nensa F, Gauler T, Gomez B, Reis H, Stamatis G, Kühl H, Hartung V, Heusner TA. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med. 2014 Mar;55(3):373-8. doi: 10.2967/jnumed.113.129825.
  • Grueneisen J, Beiderwellen K, Heusch P, Gratz M, Schulze-Hagen A, Heubner M, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L. Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging for Whole-Body Staging in Patients With Recurrent Gynecological Malignancies of the Pelvis: A Comparison to Whole-Body Magnetic Resonance Imaging Alone. Invest Radiol. 2014 Jul 9.
  • Beiderwellen K, Huebner M, Heusch P, Grueneisen J, Ruhlmann V, Nensa F, Kuehl H, Umutlu L, Rosenbaum-Krumme S, Lauenstein TC. Whole-body [¹?F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results. Eur Radiol. 2014 Aug;24(8):2023-30.
  • Grueneisen J, Schaarschmidt BM, Beiderwellen K, Schulze-Hagen A, Heubner M, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L. Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies. J Nucl Med. 2014 Dec;55(12):1930-5. doi: 10.2967/jnumed.114.146886.
  • Grueneisen J, Beiderwellen K, Heusch P, Buderath P, Aktas B, Gratz M, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L. Correlation of standardized uptake value and apparent diffusion coefficient in integrated whole-body PET/MRI of primary and recurrent cervical cancer. PLoS One. 2014 May 7;9(5):e96751.
  • Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P, Kraff O, Forsting M, Lauenstein TC, Umutlu L. [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):56-65. doi: 10.1007/s00259-014-2902-8. Epub 2014 Sep 16.
  • Schaarschmidt B, Buchbender C, Gomez B, Rubbert C, Hild F, Köhler J, Grueneisen J, Reis H, Ruhlmann V, Wetter A, Quick HH, Antoch G, Heusch P. Thoracic staging of non-small-cell lung cancer using integrated 18F-FDG PET/MR imaging: diagnostic value of different MR sequences. Eur J Nucl Med Mol Imaging. 2015 Apr 8.
  • Schaarschmidt BM, Grueneisen J, Heusch P, Gomez B, Umutlu L, Ruhlmann V, Rosenbaum-Krumme S, Antoch G, Buchbender C. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT? Nucl Med Commun. 2015 Mar 10.
  • Schaarschmidt BM, Buchbender C, Nensa F, Grueneien J, Gomez B, Köhler J, Reis H, Ruhlmann V, Umutlu L, Heusch P. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI. PLoS One. 2015 Jan 9;10(1):e0116277. doi: 10.1371/journal.pone.0116277. eCollection 2015.
  • Heusch P, Nensa F, Schaarschmidt B, Sivanesapillai R, Beiderwellen K, Gomez B, Köhler J, Reis H, Ruhlmann V, Buchbender C. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):42-8.
  • Beiderwellen K, Geraldo L, Ruhlmann V, Heusch P, Gomez B, Nensa F, Umutlu L, Lauenstein TC. Accuracy of [18F]FDG PET/MRI for the Detection of Liver Metastases. PLoS One. 2015 Sep 3;10(9):e0137285.
  • Grueneisen J, Schaarschmidt BM, Heubner M, Suntharalingam S, Milk I, Kinner S, Heubner A, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L. Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: A comparison to PET/CT. Eur J Radiol. 2015 Nov;84(11):2097-102.
  • Schaarschmidt BM, Heusch P, Buchbender C, Ruhlmann M, Bergmann C, Ruhlmann V, Schlamann M, Antoch G, Forsting M, Wetter A. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI. Eur J Nucl Med Mol Imaging. 2015 Aug 6.
  • Grueneisen J, Schaarschmidt BM, Heubner M, Aktas B, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L. Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1814-24.
  • Buchbender C, Ostendorf B, Ruhlmann V, Heusch P, Miese F, Beiderwellen K, Schneider M, Braun J, Antoch G, Baraliakos X. Hybrid 18F-labeled Fluoride Positron Emission Tomography/Magnetic Resonance (MR) Imaging of the Sacroiliac Joints and the Spine in Patients with Axial Spondyloarthritis: A Pilot Study Exploring the Link of MR Bone Pathologies and Increased Osteoblastic Activity. J Rheumatol. 2015 Sep;42(9):1631-7.
  • Schaarschmidt BM, Grueneisen J, Heusch P, Gomez B, Beiderwellen K, Ruhlmann V, Umutlu L, Quick HH, Antoch G, Buchbender C. Oncological whole-body staging in integrated (18)F-FDG PET/MR: Value of different MR sequences for simultaneous PET and MR reading. Eur J Radiol. 2015 Jul;84(7):1285-92.
  • Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V, Umutlu L, Antoch G, Heusch P. Evaluation of the Outcome of Lung Nodules Missed on 18F-FDG PET/MRI Compared with 18F-FDG PET/CT in Patients with Known Malignancies. J Nucl Med. 2016 Jan;57(1):15-20.
  • Ruhlmann V, Heusch P, Kühl H, Beiderwellen K, Antoch G, Forsting M, Bockisch A, Buchbender C, Quick HH. Potential influence of Gadolinium contrast on image segmentation in MR-based attenuation correction with Dixon sequences in whole-body 18F-FDG PET/MR. Magn Reson Mater Phy. 2016 Apr;29(2):301-8. doi: 10.1007/s10334-015-0516-1.
  • Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V, Wetter A, Umutlu L, Antoch G, Heusch P. Comparative Performance of 18F-FDG PET/MRI and 18F-FDG PET/CT in Detection and Characterization of Pulmonary Lesions in 121 Oncologic Patients. J Nucl Med. 2016 Apr;57(4):582-6.
  • Schaarschmidt BM, Grueneisen J, Metzenmacher M, Gomez B, Gauler T, Roesel C, Heusch P, Ruhlmann V, Umutlu L, Antoch G, Buchbender C. Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT? Eur Radiol. 2016 May 14. [Epub ahead of print]
  • Grueneisen J, Sawicki LM, Schaarschmidt BM, Suntharalingam S, von der Ropp S, Wetter A, Ruhlmann V, Quick HH, Forsting M, Umutlu L. Evaluation of a Fast Protocol for Staging Lymphoma Patients with Integrated PET/MRI. PLoS One. 2016 Jun 21;11(6):e0157880. doi: 10.1371/journal.pone.0157880.
  • Ruhlmann M, Jentzen W, Ruhlmann V, Pettinato C, Rossi G, Binse I, Bockisch A, Rosenbaum-Krumme S. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases. J Nucl Med. 2016 Sep;57(9):1339-42. doi: 10.2967/jnumed.115.169649.
  • Ruhlmann V, Poeppel TD, Brandt AS, Grueneisen J, Ruhlmann M, Theysohn JM, Forsting M, Bockisch A, Umutlu L. 18F-FDG-PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease. Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1646-52. doi: 10.1007/s00259-016-3351-3. Erratum in: Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1395.
  • Ruhlmann V, Ruhlmann M, Bellendorf A, Grueneisen J, Sawicki LM, Grafe H, Forsting M, Bockisch A, Umutlu L. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT. Eur J Radiol. 2016 Nov;85(11): 1941-1947. doi: 10.1016/j.ejrad.2016.08.020.
  • Schaarschmidt BM, Gomez B, Buchbender C, Grueneisen J, Nensa F, Sawicki LM, Ruhlmann V, Wetter A, Antoch G, Heusch P. Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area? Diagn Interv Radiol. 2017 Mar-Apr;23(2):127-132. doi: 10.5152/dir.2016.15610.
  • Kirchner J, Sawicki LM, Suntharalingam S, Grueneisen J, Ruhlmann V, Aktas B, Deuschl C, Herrmann K, Antoch G, Forsting M, Umutlu L. Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT. PLoS One. 2017 Feb 22;12(2):e0172553. doi: 10.1371/journal.pone.0172553. eCollection 2017.
  • Grueneisen J, Sawicki LM, Wetter A, Kirchner J, Kinner S, Aktas B, Forsting M, Ruhlmann V, Umutlu L. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients. Eur J Radiol. 2017 Apr;89:14-19. doi: 10.1016/j.ejrad.2016.12.019. Epub 2017 Jan 22.
  • Sawicki LM, Deuschl C, Beiderwellen K, Ruhlmann V, Poeppel TD, Heusch P, Lahner H, Führer D, Bockisch A, Herrmann K, Forsting M, Antoch G, Umutlu L. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT. Eur Radiol. 2017 Apr 24. doi: 10.1007/s00330-017-4803-2.
  • Ruhlmann M, Ruhlmann J, Görges R, Herrmann K, Antoch G, Keller HW, Ruhlmann V. 18F-FDG PET/CT may exclude malignancy in sonographically suspicious and scintigraphically hypofunctional thyroid nodules and reduce unnecessary thyroid surgeries. Thyroid. 2017 Aug 10. doi: 10.1089/thy.2017.0026.
  • Schenke SA, Kreissl MC, Grunert M, Hach A, Haghghi S, Kandror T, Peppert E, Rosenbaum-Krumme S, Ruhlmann V, Stahl A, Wanjura D, Zaplatnikov K, Zimny M, Hilman E, Herrmann K, Görges R. Distribution of functional status of thyroid nodules and malignancy rates of hyperfunctioning and hypofunctioning thyroid nodules in Germany. Nuklearmedizin. 2022. doi: 10.1055/a-1856-4052.
  • Baumgarten J, Schenke SA, Raffa A, Ruhlmann V, Campenni A. Una panoramica sull’attuale utilizzo in Europa della scintigrafia con 99mTc-MIBI nei noduli tiroidei a citologia indeterminate. An overview on current European use of qualitative and semiquantitative 99mTc-MIBI scintigraphy in cytologically indeterminate thyroid noduleL’Endocrinologo 15 March 2023. Published online 19 September 2023. https://doi.org/10.1007/s40619-023-01354-y.
  • Schenke SA, Petersen M, Görges R, Ruhlmann V, Zimnny Michael, Richter JP, Groener D, Baumgarten J, Kreissl MC, Stahl A, Grunert M, Klemenz B, Veit F, Zettinig G, Seifert P. Interobserver Agreement in Ultrasound Risk Stratification Systems for Thyroid Nodules on Static Images Versus Cine-Loop Video Sequences.Diagnostics2024,14,2138. https://doi.org/10.3390/diagnostics14192138. 

Übersichtsarbeiten in Zeitschriften

  • Bockisch A, Sonnenschein W, Jentzen W, Hartung V, Görges R. Dosimetrie bei Radiojodtherapie benigner Schilddrüsenerkrankungen – Hintergrund und Durchführung. Der Nuklearmediziner 2008; 31: 253-262.
  • Görges R, Hartung V, Herrmann B.L., Bockisch A, Freudenberg L S. Tumormarker für Schilddrüsenkarzinome. TumorDiagnostik und Therapie (TumorDiagn u Ther) 2010; 31: 29-38.
  • Nagarajah J, Hartung V, Jentzen W, Bockisch A, Stahl A. PET/MR versus PET/CT: Detektion von Schilddrüsenrestgewebe und Lymphknoten bei I-124-Dosimetriepatienten. Med-Report 2010, Wiley-Blackwell.
  • Ruhlmann V, Ruhlmann M, Beiderwellen K, Lauenstein T. Ganzkörper-MRT. Der Nuklearmediziner 2014; 37: 83-89.
  • Beiderwellen K, Ruhlmann V, Lazik A. MRT des Skelettsystems in der Onkologie. Der Nuklearmediziner 2014; 37: 73-76.
  • Stegger L, Ruhlmann V. PET/MRT - Ein neues Verfahren der klinischen Hybridbildgebung. Der Nuklearmediziner 2014; 37: 101-108.
  • Schlamann M, Ruhlmann V, Quick HH. Hybridbildgebung in der Neuroradiologie. Der Neurologe & Psychiater 2015; 16 (4): 40-46.

Buchkapitel

  • Hartung V, Ruhlmann M, Bockisch A, Nagarajah J. Tumor Imaging with 123/131I-MIBG-SPECT. SPECT Technology, Procedures And Applications 2013; 7: 133-146.
  • Ruhlmann M, Ruhlmann V, Jentzen W, Bockisch A. 124I PET: Pretherapeutic staging, detection of recurrent thyroid cancer and dosimetry. Thyroid Cancer – Advances in Diagnosis and Therapy 2016. http://dx.doi.org/10.5772/63671. ISBN 978-953-51-4798-5.